Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Triamcinolone Hexacetonide

FDA-approved product (injectable, injection), marketed as Aristospan.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Triamcinolone Hexacetonide
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Airway obstruction
  • Eye inflammation
  • Hemorrhoid
  • Nasal congestion
  • Osteoarthritis
  • Skin disease

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Corticosteroids for local oral treatment; Corticosteroids; Corticosteroids, moderately potent (group ii); Corticosteroids, moderately potent, other combinations; Glucocorticoids
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA. It was surfaced computationally for further investigation; it is not an established treatment for this infection.

AI-predicted activity

AI prediction · nothing measured
  • MRSA53.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli36.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae28.3% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis36.1% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Triamcinolone Hexacetonide in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.7 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.6 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-9.7 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-8.1 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Triamcinolone Hexacetonide with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Intravitreal Triamcinolone Acetonide for Treatment of Refractory Diffuse Diabetic Macular Edema

    NCT00407849 · start 2006-10

    Registered record
    Registry ID
    NCT00407849
    Conditions
    Diabetic Retinopathy
    Interventions
    triamcinolone acetonide
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Unknown
    Start
    2006-10
    Completion
    2008-08
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDiabetic Retinopathy
    Interventiontriamcinolone acetonide
    PhasePhase 1 / Phase 2
    Registry statusUnknown

  • Efficacy and Safety of Intravitreal Triamcinolone Acetonide in Eyes With Post Vitrectomy Diabetic Vitreous Hemorrhage

    NCT00300014 · start 2006-01

    Registered record
    Registry ID
    NCT00300014
    Conditions
    Post Vitrectomy State; Recurrent Diabetic Vitreous Hemorrhage
    Interventions
    Intravitreal triamcinolone injection; Air-fluid exchange
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2006-01
    Completion
    2007-05
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPost Vitrectomy State; Recurrent Diabetic Vitreous Hemorrhage
    InterventionIntravitreal triamcinolone injection; Air-fluid exchange
    PhaseNot applicable
    Registry statusUnknown

  • Tacrolimus Ointment in Oral Lichen Planus

    NCT01544842 · start 2004-08

    Registered record
    Registry ID
    NCT01544842
    Conditions
    Oral Lichen Planus
    Interventions
    0.1 % tacrolimus ointment; 0.1 % triamcinolone paste; Orabase paste
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Terminated
    Start
    2004-08
    Completion
    2015-07
    Enrolment
    28

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOral Lichen Planus
    Intervention0.1 % tacrolimus ointment; 0.1 % triamcinolone paste; Orabase paste
    PhaseNot applicable
    Registry statusTerminated

  • Using Ultrasound to Predict Response to Intraarticular Corticosteroids in Knee Osteoarthritis

    NCT00746889 · start 2004-03

    Registered record
    Registry ID
    NCT00746889
    Conditions
    Osteoarthritis
    Interventions
    triamcinolone acetonide; saline
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2004-03
    Completion
    2008-09
    Enrolment
    79

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOsteoarthritis
    Interventiontriamcinolone acetonide; saline
    PhaseNot applicable
    Registry statusCompleted

  • Effects of Long-Term Treatment With Nasally Inhaled Triamcinolone Acetonide in Children With Allergic Rhinitis

    NCT00189449

    Registered record
    Registry ID
    NCT00189449
    Conditions
    Allergic Rhinitis; Allergy; Growth
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    Not recorded
    Completion
    2007-06
    Enrolment
    Not recorded

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAllergic Rhinitis; Allergy; Growth
    InterventionNot recorded
    PhaseNot recorded
    Registry statusCompleted